Latest 10-K annual reports
NASDAQ
Lesaka Technologies, Inc. filed an amended 10-K to provide executive compensation and corporate governance details for fiscal year 2025, previously omitted from its annual report.
NASDAQ
The Ensign Group, Inc. reported an 18.7% increase in total revenue for 2025, driven by strategic acquisitions and improved occupancy in its skilled nursing and senior living facilities.
NYSE
Terreno Realty Corporation reported significant growth in 2025, driven by strategic industrial property acquisitions, increased rental rates, and strong operational performance, alongside a new term loan and dividend increase.
OID
Public Company Management Corporation (PCMC) reports substantial doubt about its ability to continue as a going concern, while actively pursuing a merger with a healthcare facilities company.
NASDAQ
Advanced Micro Devices, Inc. filed an amendment to its 2025 annual report to correct transposed figures for Client segment unit shipments and average selling price, while reporting significant growth in Data Center and Client & Gaming segments.
NASDAQ
Lakeshore Acquisition III Corp., a blank check company, reported a net income of $1.26 million for 2025, but faces substantial doubt about its ability to continue as a going concern without a business combination.
NASDAQ
Mondelēz International reports a significant drop in 2025 net earnings and EPS, driven by soaring input costs and unfavorable volume/mix, despite revenue growth.
NASDAQ
Manhattan Associates exceeded expectations in 2025 with a 21% surge in cloud subscription revenue and a 7% increase in operating income, driven by solid demand for its cloud solutions.
NASDAQ
Reynolds Consumer Products Inc. reported a 1% increase in total net revenues to $3.721 billion for fiscal year 2025, despite a 14% decrease in net income to $301 million, driven by higher input costs and strategic initiative expenses.
NASDAQ
Regeneron Pharmaceuticals reports increased net income and diluted EPS in 2025, driven by strong Dupixent sales, despite a significant decline in U.S. EYLEA revenue and ongoing regulatory and legal challenges.
NASDAQ
GE HealthCare Technologies Inc. reported a 4.8% increase in total revenues for 2025, reaching $20.6 billion, driven by strong performance in its PDx, Imaging, and AVS segments, despite significant tariff impacts and a decline in its PCS segment.
NASDAQ
Ares Capital Corporation's 2025 annual report reveals robust investment activity, increased total assets, and strategic capital management, reinforcing its position as a leading BDC despite a slight dip in net investment income and unrealized losses.
NASDAQ
PayPal Holdings, Inc. announced a significant increase in net income and diluted EPS for fiscal year 2025, driven by strategic focus on profitable growth and value-added services, despite a decline in payment transactions.
NYSE
KKR Real Estate Finance Trust Inc. reported a net loss attributable to common stockholders of $69.9 million for 2025, driven by increased credit loss provisions, despite strategic financing improvements.
NASDAQ
Intuitive Surgical achieved significant revenue and procedure growth in 2025, fueled by strong adoption of its da Vinci surgical systems, particularly the new da Vinci 5, and expanding use of the Ion endoluminal system.
NYSE
MMM
3m CO3M delivered slight sales growth in 2025, lifted margins on an adjusted basis, completed its PFAS manufacturing exit, and advanced major legal settlements while boosting dividends and buybacks.
NASDAQ
CMCSA
Comcast CORPComcast reports mixed 2025 results with a Versant spin-off, Hulu sale gain, and continued broadband subscriber losses offset by wireless growth and theme park expansion.
NYSE
Teva Pharmaceutical Industries Limited reported a 4% increase in 2025 revenues, driven by strong performance in key innovative products and strategic pipeline advancements, despite declines in certain generic markets.
NYSE
DOW
Dow INCDow Inc. posted a substantial net loss in 2025, driven by declining sales, goodwill impairment, and extensive restructuring efforts in a challenging macroeconomic environment.
NYSE
Liberty Energy Inc. reported a 7% revenue decrease in 2025, alongside a strategic expansion into distributed power solutions and significant leadership changes.
NASDAQ
Skyworks Solutions, Inc. reports strong fiscal year 2025 operational performance, surpassing revenue and operating income targets, while navigating significant executive leadership changes.
OQB
Innovative Designs, Inc. reported a 100% revenue increase and significant net income growth for fiscal year 2025, primarily driven by its House Wrap segment, despite ongoing concerns about its ability to continue as a going concern.
OQX
Nobility Homes, Inc. reported a slight increase in net sales for fiscal year 2025, reaching $52.7 million, despite a decrease in net income and ongoing industry challenges.
NYSE
Boeing reports a return to net earnings in 2025 driven by higher deliveries and a major divestiture gain, despite ongoing production challenges and significant losses in its commercial and defense segments.
NYSE
General Dynamics reported robust financial performance in 2025 with double-digit revenue growth, increased earnings, and a record $118 billion backlog, driven by strong demand across its aerospace and defense segments.
OTC.Pink
Non-Invasive Monitoring Systems, Inc. (NIMS) reported increased net losses and a deteriorating financial position, raising substantial doubt about its ability to continue as a going concern.
NASDAQ
GRI
Gri Bio, INCGRI Bio, Inc. announced positive topline results from its Phase 2a clinical trial for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), while also disclosing substantial doubt about its ability to continue as a going concern.
NASDAQ
Charter Communications reports a slight revenue decrease for 2025, driven by video and advertising declines, but sees strong mobile line growth and network expansion progress.
NYSE
Lockheed Martin reported increased sales and free cash flow in 2025, but net earnings and EPS declined due to significant program losses and a pension settlement charge.
OQB
Pharma-Bio Serv, Inc. reported a significantly reduced net loss of $0.1 million for fiscal year 2025, driven by strong European market growth and improved gross profit margins, despite an overall revenue decline.